Last updated: 2026-09-05 08:15:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Metagenomi Therapeutics, Inc. (MGX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.17, with a market capitalization of $43.82M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.13 to $3.95. This page covers its latest market performance, valuation, price trends and company information.
$43.82M | |
$1.14 | |
$12.74 | |
$1.13 | |
$1.16 | |
54.44K | |
-- | |
-- | |
$3.95 | |
$1.13 | |
-- | |
-- |
Metagenomi Therapeutics, Inc. (MGX) last closed at $1.16 as of 2026-09-04 23:49:00, unchanged from the previous close of $1.16.
During the latest regular trading session, MGX traded between $1.13 and $12.74, with a volume of 54.44K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Metagenomi Therapeutics, Inc. (MGX) moved from $1.18 to $1.17, representing a decline of 1.27% ($0.01).
The stock traded between $1.14 and $1.18 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 133.48 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.3%
MGX is currently trading at $1.17, placing it 1.3% of the way from its 52-week low of $1.13 to its 52-week high of $3.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 113 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Metagenomi Therapeutics, Inc. (MGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.